Status: Recruiting
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Participants needed: 130
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: RTOG Foundation, Inc.Updated: Oct 2, 2026Locations: 17
Eligibility criteria
Aged >= 18 years [+23]
Patients with a clinical diagnosis of NF2-related schwannomatosis or with a know... [+21]